Enhancement of stem cell engraftment on a WHIM
dc.contributor.author | Broxmeyer, Hal E. | |
dc.contributor.department | Microbiology and Immunology, School of Medicine | en_US |
dc.date.accessioned | 2019-10-12T12:04:35Z | |
dc.date.available | 2019-10-12T12:04:35Z | |
dc.date.issued | 2018-08-01 | |
dc.description.abstract | WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a genetic autoimmune disorder that results from gain-of-function mutations in the gene encoding chemokine receptor CXCR4. A previous study characterized a patient with WHIM who underwent a chromothriptic event that resulted in spontaneous deletion of the WHIM allele in a single hematopoietic stem cell and subsequent cure of the disease. In this issue of the JCI, Gao et al. extend this work and show that Cxcl4-haplosufficient bone marrow has a selective advantage for long-term engraftment in murine WHIM models. Moreover, successful engraftment occurred without prior conditioning of recipients. Together, these results have important implications for improving hematopoietic stem/progenitor cell transplant not only for patients with WHIM but also for all patients who may require the procedure. | en_US |
dc.identifier.citation | Broxmeyer H. E. (2018). Enhancement of stem cell engraftment on a WHIM. The Journal of clinical investigation, 128(8), 3240–3242. doi:10.1172/JCI121857 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/21142 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Society for Clinical Investigation | en_US |
dc.relation.isversionof | 10.1172/JCI121857 | en_US |
dc.relation.journal | The Journal of Clinical Investigation | en_US |
dc.source | PMC | en_US |
dc.subject | Agammaglobulinemia | en_US |
dc.subject | Bone Marrow Transplantation | en_US |
dc.subject | Immunologic Deficiency Syndromes | en_US |
dc.subject | Receptors, CXCR4 | en_US |
dc.title | Enhancement of stem cell engraftment on a WHIM | en_US |
dc.type | Article | en_US |